Management of Atenolol-Associated Angioedema

Introduction to Angioedema Management

• The American College of Cardiology recommends that beta-blockers like atenolol remain a Class I, Level A recommendation for heart failure with reduced ejection fraction and are not contraindicated in patients with angioedema 1
• ACE inhibitors cause angioedema in less than 1% of patients through impaired degradation of bradykinin and substance P, occurring more frequently in Black patients and women 2, 3, 4

Medication Safety and Angioedema Risk

• The American Heart Association implies that all beta-blockers, including atenolol, are safe to continue as they do not interact with the bradykinin pathway 1
• The American College of Cardiology states that ACE inhibitors are absolutely contraindicated for life if ACE inhibitor angioedema is confirmed 2, 4
• ARBs have a 2-17% recurrence risk in patients with prior ACE inhibitor angioedema, though most tolerate them safely 2, 3, 4

Acute Angioedema Management

• Airway management is the absolute priority, with monitoring in a facility capable of intubation or tracheostomy 4
• Traditional therapies, such as antihistamines, corticosteroids, and epinephrine, are not effective for bradykinin-mediated angioedema 3, 4
• Targeted therapies, including icatibant and fresh frozen plasma, may be considered for acute management 3, 4